HOME Research Insight Terumo BCT and HemaCare Corporation are Leading Players in Leukapheresis Market

Terumo BCT and HemaCare Corporation are Leading Players in Leukapheresis Market

Terumo BCT (US), Fresenius (Germany), Asahi Kasei Medical (Japan), and Haemonetics Corporation (US) are the leading players in the leukapheresis products market. The global leukapheresis products market is projected to reach USD 27.7 million by 2023 from USD 19.4 million in 2018, at a CAGR of 7.4%. HemaCare Corporation (US), AllCells (US), BioIVT (US), and Precision for Medicine (US) are the leading players in the leukopaks market. The global leukopaks market is projected to reach USD 445.6 million by 2023, at a CAGR of 46.4%.

Factors such as rising incidence and prevalence of leukemia and a growing demand for leukopaks are the key factors driving the growth of the leukapheresis market. In addition, the number of blood donations has grown in recent years, thereby ensuring the steady uptake of apheresis for the separation of blood components. The use of leukapheresis in pediatric patients is also being explored, making this an area of opportunity in the market. However, the high cost of therapeutic leukapheresis and leukopaks, the stringent regulations for leukocyte donor recruitment, and complications associated with therapeutic leukapheresis may restrain the growth of this market to a certain extent.

Major players in the global leukapheresis products market include Asahi Kasei Medical. (Japan), Fresenius SE & (Germany), Haemonetics (US), Terumo BCT (US), STEMCELL Technologies (Canada), Macopharma (France), Nikkiso (Japan), and Miltenyi Biotec (Germany). Some prominent players in the global leukopaks market are HemaCare Corporation (US), AllCells (US), StemExpress (US), PPA Research Group (US), Key Biologics (US), Caltag Medsystem (UK), ZenBio (US), Precision for Medicine (US), and BioIVT (US). These companies adopted strategies such as acquisitions, partnerships, agreements, collaborations, expansions, and product launches to enhance their presence in the leukapheresis products and leukopaks market.

To know the Insights download the pdf brochure

Terumo BCT is a leading player in the leukapheresis products market and accounted for the largest share of the market in 2017. The company offers apheresis equipment with the WBC removal protocol. The company has a strong geographic presence through its various subsidiaries established across the globe—Terumo BCT Latin America S.A. in Argentina, Terumo BCT Europe N.V. in Belgium, and Terumo BCT (Asia Pacific) Ltd. in Hong Kong. The company focuses on expanding its presence to new and emerging economies like Vietnam, Belgium, and Northern Ireland. In July 2014, the company opened a manufacturing facility near Ho Chi Minh City, Vietnam.

HemaCare Corporation accounted for the largest share in leukopaks market in 2017. The company grew by 45.6% in 2017 compared to the previous year. This growth was mainly driven by international expansions and improved sales from the company’s key distributors, i.e. direct cell therapy customers, such as Novartis. The company’s business in Europe, Japan, and China is growing substantially. HemaCare also focuses on increasing its scalability in terms of quantity and quality to support the growing demand for leukopaks from research organizations for the development of cellular therapy technologies.

Related Reports:

Leukapheresis Market by Product (Apheresis Machine, Leukocyte Filter, Column, Disposables), Leukopak (Mobilized, Non-Mobilized, Human Primary Cells), Application (Research, Therapeutic), End User (Hospitals, Research Institute) - Global Forecast to 2023

Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441

Connect Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support

US : 1-888-600-6441

Search reports